In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
OBJECTIVE
To evaluate bropirimine for in vivo activity in rodent prostate cancer.


METHODS
Subcutaneously injected PAIII and Dunning MAT-LyLu rodent prostate cancer cells caused solid tumors and death in controls. Bropirimine was given on varying schedules at 250 mg./kg. by gavage, and tumor volume and survival were recorded.


RESULTS
Bropirimine prevented growth when given on the day of tumor injection and caused 95% of advanced tumors to regress completely in the PAIII model. Bropirimine caused significant growth inhibition and prolongation of survival in the MAT-LyLu model.


CONCLUSIONS
Bropirimine has statistically significant in vivo activity against both of these rodent prostate cancer cell lines.
Sarosdy
M F
MF
Division of Urology, University of Texas Health Science Center at San Antonio 78284-7845, USA.
Higdon
A L
AL
Demoor
C A
CA
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D003596:Cytosine; C033560:bropirimine